Poor Prognosis Colorectal Cancers Display Self-sustained Growth by Niche-mimicry
This project investigates how mesenchymal colorectal cancers achieve self-sustained growth through niche-mimicry, aiming to enhance understanding of tumor biology and inform new treatment strategies.
Projectdetails
Introduction
Colorectal cancer (CRC) is a heterogeneous disease with widely variable clinical outcomes. I previously contributed to a unifying molecular classification of CRC, the consensus molecular subtypes (CMSs). The mesenchymal subtype (CMS4), representing ~25% of all CRC patients, is characterised by early metastatic dissemination and poor response to therapy.
Research Focus
This is often attributed to activated and rich stroma, and therefore much attention in the field goes to dissecting the interaction of the mesenchyme with the cancer cells in these tumours. However, in this research program, I will investigate a radically different hypothesis: mesenchymal CRCs display self-sustained growth by niche-mimicry (nimicry).
Definition of Nimicry
I define nimicry as the adoption of niche features by cancer cells, thereby rendering the cancers independent of micro-environmental signals for their expansion. This hypothesis is directly based on preliminary experiments from my laboratory, which demonstrated that mesenchymal CRCs are not dependent on external growth factors for expansion in vitro and display autocrine and paracrine loops that drive self-sustained growth.
Role of Stroma
The abundant stroma in mesenchymal CRCs is secondary to the growth factors and cytokines produced by the tumour cells.
Methodology
To study this concept, I will employ primary human CRC models in combination with molecular and functional characterisation to delineate the self-supporting signalling loops in a patient-specific fashion.
Clonal Dynamics Investigation
These studies are paralleled by the investigation of clonal dynamics within established human CRCs by means of a novel genetic lineage tracing strategy in combination with quantitative analysis. Dedicated analyses will resolve the impact of nimicry on:
- Metastasis formation
- Therapy resistance
- Tumour evolution
Conclusion
These studies into nimicry as a critical concept in tumour biology will importantly advance our understanding of the signals that drive CRC growth and progression, and will pave the way to new treatment strategies.
Financiële details & Tijdlijn
Financiële details
Subsidiebedrag | € 1.949.357 |
Totale projectbegroting | € 1.949.357 |
Tijdlijn
Startdatum | 1-10-2022 |
Einddatum | 30-9-2027 |
Subsidiejaar | 2022 |
Partners & Locaties
Projectpartners
- STICHTING AMSTERDAM UMCpenvoerder
Land(en)
Vergelijkbare projecten binnen European Research Council
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Functional characterization of the colorectal cancer metastasis microbiomeThe METABAC project aims to investigate the functional roles of bacteria in colorectal cancer metastasis using innovative platforms to uncover their impact on cancer progression and potential therapeutic targets. | ERC Starting... | € 1.499.894 | 2024 | Details |
Regaining control of cancer at biological bordersBorderControl aims to identify molecular signals and mechanisms that enable cancer cells to breach physiological barriers, with the goal of uncovering novel biomarkers and therapeutic targets for metastasis. | ERC Advanced... | € 2.500.000 | 2024 | Details |
High throughput phylogeography of tumors: how the tissue environment influences cancer evolution?This project aims to develop transcriptional phylogeography to study tumor evolution in situ at single-cell resolution, linking tumor microenvironment characteristics to sub-clonal properties. | ERC Consolid... | € 2.000.000 | 2023 | Details |
Harnessing Stromal Fibroblasts to Reduce Resistance and Improve Colon Cancer TherapeuticsThis project aims to understand how cancer-associated fibroblasts influence drug resistance in colorectal cancer, using mechanotransduction pathways to develop biomarkers and improve therapeutic efficacy. | ERC Consolid... | € 1.999.826 | 2022 | Details |
Mechanobiology of cancer progressionThis project aims to develop an innovative in vivo platform to study tumor fibrosis and improve targeted cancer therapies by mimicking the fibrotic microenvironment of breast cancer. | ERC Advanced... | € 2.498.690 | 2022 | Details |
Functional characterization of the colorectal cancer metastasis microbiome
The METABAC project aims to investigate the functional roles of bacteria in colorectal cancer metastasis using innovative platforms to uncover their impact on cancer progression and potential therapeutic targets.
Regaining control of cancer at biological borders
BorderControl aims to identify molecular signals and mechanisms that enable cancer cells to breach physiological barriers, with the goal of uncovering novel biomarkers and therapeutic targets for metastasis.
High throughput phylogeography of tumors: how the tissue environment influences cancer evolution?
This project aims to develop transcriptional phylogeography to study tumor evolution in situ at single-cell resolution, linking tumor microenvironment characteristics to sub-clonal properties.
Harnessing Stromal Fibroblasts to Reduce Resistance and Improve Colon Cancer Therapeutics
This project aims to understand how cancer-associated fibroblasts influence drug resistance in colorectal cancer, using mechanotransduction pathways to develop biomarkers and improve therapeutic efficacy.
Mechanobiology of cancer progression
This project aims to develop an innovative in vivo platform to study tumor fibrosis and improve targeted cancer therapies by mimicking the fibrotic microenvironment of breast cancer.
Vergelijkbare projecten uit andere regelingen
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Next-Generation Drug Discovery Platform for Targeting Cancer Stem Cell PathwaysDevelop a drug discovery platform using patient-derived organoids and machine learning to target stem cell signaling pathways in colorectal cancer, aiming to improve treatment outcomes. | EIC Transition | € 2.433.125 | 2022 | Details |
Next-Generation Drug Discovery Platform for Targeting Cancer Stem Cell Pathways
Develop a drug discovery platform using patient-derived organoids and machine learning to target stem cell signaling pathways in colorectal cancer, aiming to improve treatment outcomes.